carbon monoxide has been researched along with Lung Diseases, Obstructive in 85 studies
Carbon Monoxide: Carbon monoxide (CO). A poisonous colorless, odorless, tasteless gas. It combines with hemoglobin to form carboxyhemoglobin, which has no oxygen carrying capacity. The resultant oxygen deprivation causes headache, dizziness, decreased pulse and respiratory rates, unconsciousness, and death. (From Merck Index, 11th ed)
carbon monoxide : A one-carbon compound in which the carbon is joined only to a single oxygen. It is a colourless, odourless, tasteless, toxic gas.
Lung Diseases, Obstructive: Any disorder marked by obstruction of conducting airways of the lung. AIRWAY OBSTRUCTION may be acute, chronic, intermittent, or persistent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to evaluate the pulmonary effects of amiodarone in patients with heart failure, in those with chronic obstructive pulmonary disease (COPD) and in those undergoing a surgical procedure." | 9.08 | Pulmonary effect of amiodarone in patients with heart failure. The Congestive Heart Failure-Survival Trial of Antiarrhythmic Therapy (CHF-STAT) Investigators (Veterans Affairs Cooperative Study No. 320). ( Deedwania, PC; Fisher, SG; Fletcher, RD; Rohatgi, P; Singh, BN; Singh, SN, 1997) |
| "The purpose of this study was to evaluate the pulmonary effects of amiodarone in patients with heart failure, in those with chronic obstructive pulmonary disease (COPD) and in those undergoing a surgical procedure." | 5.08 | Pulmonary effect of amiodarone in patients with heart failure. The Congestive Heart Failure-Survival Trial of Antiarrhythmic Therapy (CHF-STAT) Investigators (Veterans Affairs Cooperative Study No. 320). ( Deedwania, PC; Fisher, SG; Fletcher, RD; Rohatgi, P; Singh, BN; Singh, SN, 1997) |
| " Rarer and thus less known are work related noxious substances (mainly nitroglycols, carbon sulfur, carbon monoxide) that lead to or at least accelerate cardiovascular diseases." | 3.69 | [Smoking in the workplace]. ( Rüegger, M, 1994) |
| "Diffusion capacity for carbon monoxide of the lung (DLCO) before-and-after exercise test and 5 routine pulmonary function tests were conducted in 16 patients with diffuse pulmonary fibrosis (DPF), 19 patients with interstitial pneumonia (IP), 17 patients with COPD, and 22 normal subjects." | 3.69 | [Diagnostic value of exercise diffusion capacity test on diffuse pulmonary fibrosis]. ( He, T; Luo, Y; Yuan, Y; Zeng, J, 1996) |
| "Pentoxifylline has been reported previously in an unblinded study to improve oxygen saturation, treadmill walk time, and resting diffusion of carbon monoxide (Dco) in patients with COPD." | 2.68 | The effects of pentoxifylline on oxygenation, diffusion of carbon monoxide, and exercise tolerance in patients with COPD. ( Causing, LA; Light, RW; Sasse, SA; Stansbury, DW, 1995) |
| "Pulmonary function changes in interstitial lung disease are characterized by loss of lung volume, increase in ratio of forced expiratory volume in 1 second to forced vital capacity, and decrease in carbon monoxide diffusion capacity." | 2.39 | Pulmonary physiology in interstitial lung disease: recent developments in diagnostic and prognostic implications. ( Baydur, A, 1996) |
| "Emphysema is the predominant lesion in persons with severe airflow obstruction due to COPD." | 2.38 | Chronic obstructive pulmonary disease: a definition and implications of structural determinants of airflow obstruction for epidemiology. ( Snider, GL, 1989) |
| "Respiratory outcomes in Mucopolysaccharidosis Type I (MPS I), have mainly focused on upper airway obstruction, with the evolution of the restrictive lung disease being poorly documented." | 1.62 | The evolution of pulmonary function in childhood onset Mucopolysaccharidosis type I. ( Broomfield, A; Ghosh, A; Hensman, P; Jones, SA; Mercer, J; Oldham, A; Prathivadi Bhayankaram, N; Sims, J; Stepien, KM; Tylee, K; Wilkinson, S; Wright, NB; Wynn, R, 2021) |
| "Carbon monoxide (CO) transfer was measured with the standard single-breath method." | 1.31 | Influence of lung parenchymal destruction on the different indexes of the methacholine dose-response curve in COPD patients. ( Boere-van der Straat, S; Bogaard, JM; Hoogsteden, HC; Verbraak, AF; Verhoeven, GT, 2000) |
| "Ethane is a product of lipid peroxidation and can be measured in the exhaled air as an index of oxidative stress." | 1.31 | Exhaled ethane, a marker of lipid peroxidation, is elevated in chronic obstructive pulmonary disease. ( Barnes, PJ; Cramer, D; Kharitonov, SA; Leak, D; Paredi, P; Ward, S, 2000) |
| "Recent studies of exercise-induced hypoxemia in patients with chronic obstructive pulmonary disease (COPD) have shown that oxygen supplementation during exertion increases exercise tolerance and alleviates dyspnea." | 1.31 | Baseline oxygen saturation predicts exercise desaturation below prescription threshold in patients with chronic obstructive pulmonary disease. ( Adair, NE; Chin, R; Dunagan, DP; Knower, MT, 2001) |
| "Silicosis was significantly associated with hyperinflation after adjusting for exposure duration, age, and smoking." | 1.30 | Pulmonary dysfunction in silica-exposed workers: a relationship to radiographic signs of silicosis and emphysema. ( Wang, X; Yano, E, 1999) |
| "Results for atherosclerotic and cerebrovascular diseases were confirmed through Poisson regression analysis." | 1.29 | Mortality and cancer morbidity in workers from an aluminium smelter with prebaked carbon anodes--Part III: Mortality from circulatory and respiratory diseases. ( Rønneberg, A, 1995) |
| "The most important results were a respiratory acidosis after intubation and simultaneous hyperoxigenation during controlled (manual) ventilation." | 1.28 | [Laboratory diagnostic monitoring of blood gas parameters in children during bronchologic studies]. ( Augst, D; Ballke, EH; Maass, B; Wiersbitzky, S; Zöllner, H, 1990) |
| "In patients with pulmonary disease, the diffusing capacity for carbon monoxide has been used to predict abnormal gas exchange in the lung." | 1.27 | Diffusing capacity for carbon monoxide as a predictor of gas exchange during exercise. ( Hansen, JE; Oren, A; Sue, DY; Wasserman, K, 1987) |
| "Hypercapnia was induced by rebreathing, and both the ventilation and the mouth pressures produced during transient airway conclusion during inspiration were obtained." | 1.26 | Hypercapnic ventilatory control in patients with chronic airflow obstruction: a follow-up study. ( Maranetra, N; Pain, MC; Zimmerman, PV, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 47 (55.29) | 18.7374 |
| 1990's | 24 (28.24) | 18.2507 |
| 2000's | 12 (14.12) | 29.6817 |
| 2010's | 1 (1.18) | 24.3611 |
| 2020's | 1 (1.18) | 2.80 |
| Authors | Studies |
|---|---|
| Broomfield, A | 1 |
| Sims, J | 1 |
| Mercer, J | 1 |
| Hensman, P | 1 |
| Ghosh, A | 1 |
| Tylee, K | 1 |
| Stepien, KM | 1 |
| Oldham, A | 1 |
| Prathivadi Bhayankaram, N | 1 |
| Wynn, R | 1 |
| Wright, NB | 1 |
| Jones, SA | 1 |
| Wilkinson, S | 1 |
| Linares, B | 1 |
| Guizar, JM | 1 |
| Amador, N | 1 |
| Garcia, A | 1 |
| Miranda, V | 1 |
| Perez, JR | 1 |
| Chapela, R | 1 |
| Harrison, RM | 1 |
| Thornton, CA | 1 |
| Lawrence, RG | 1 |
| Mark, D | 1 |
| Kinnersley, RP | 1 |
| Ayres, JG | 1 |
| Suzuki, T | 1 |
| Yoshimi, K | 1 |
| Ueki, J | 1 |
| Fukuchi, Y | 1 |
| Zheng, JP | 1 |
| Mookherjee, S | 1 |
| Ashutosh, K | 1 |
| Smulyan, H | 1 |
| Vardan, S | 1 |
| Warner, R | 1 |
| Widimský, J | 1 |
| Tartulier, M | 1 |
| Zielinski, J | 1 |
| Frídl, P | 1 |
| Peters-Golden, M | 1 |
| Wise, RA | 1 |
| Hochberg, MC | 1 |
| Stevens, MB | 1 |
| Wigley, FM | 1 |
| Musk, AW | 1 |
| Ebert, RV | 1 |
| McNabb, ME | 1 |
| McCusker, KT | 1 |
| Snow, SL | 1 |
| Graham, BL | 1 |
| Mink, JT | 1 |
| Cotton, DJ | 2 |
| Rubin, DZ | 2 |
| Lewis, SM | 2 |
| Mittman, C | 2 |
| Turino, GM | 1 |
| Zimmerman, PV | 1 |
| Maranetra, N | 1 |
| Pain, MC | 1 |
| Cavatorta, A | 1 |
| Mutti, A | 1 |
| Frigeri, G | 1 |
| Falzoi, M | 1 |
| Cigala, F | 1 |
| Franchini, I | 1 |
| Sasse, SA | 1 |
| Causing, LA | 1 |
| Stansbury, DW | 1 |
| Light, RW | 1 |
| Kiss, D | 1 |
| Popp, W | 1 |
| Wagner, C | 1 |
| Havelec, L | 1 |
| Sertl, K | 1 |
| Crowley, TJ | 3 |
| Macdonald, MJ | 2 |
| Walter, MI | 1 |
| Rønneberg, A | 1 |
| Rüegger, M | 1 |
| Barreto, SS | 1 |
| McClean, PA | 1 |
| Szalai, JP | 1 |
| Zamel, N | 1 |
| Izquierdo-Alonso, JL | 1 |
| Juretschke-Moragues, MA | 1 |
| Ramos-Martos, A | 1 |
| Castelao-Naval, J | 1 |
| Sánchez-Hernández, I | 1 |
| Rodríguez-Glez Moro, JM | 1 |
| Moolgavkar, SH | 1 |
| Luebeck, EG | 1 |
| Anderson, EL | 1 |
| Singh, SN | 1 |
| Fisher, SG | 1 |
| Deedwania, PC | 1 |
| Rohatgi, P | 1 |
| Singh, BN | 1 |
| Fletcher, RD | 1 |
| Baydur, A | 1 |
| Yuan, Y | 1 |
| Luo, Y | 1 |
| Zeng, J | 1 |
| He, T | 1 |
| MacIntyre, NR | 1 |
| Harré, ES | 1 |
| Price, PD | 1 |
| Ayrey, RB | 1 |
| Toop, LJ | 1 |
| Martin, IR | 1 |
| Town, GI | 1 |
| Jansons, H | 1 |
| Fokkens, JK | 1 |
| van der Tweel, I | 1 |
| Kreukniet, J | 1 |
| Wang, X | 1 |
| Yano, E | 1 |
| Akesson, U | 1 |
| Dahlström, JA | 1 |
| Wollmer, P | 1 |
| Togores, B | 1 |
| Bosch, M | 1 |
| Agustí, AG | 1 |
| Stam, H | 1 |
| Splinter, TA | 1 |
| Versprille, A | 1 |
| Verhoeven, GT | 1 |
| Verbraak, AF | 1 |
| Boere-van der Straat, S | 1 |
| Hoogsteden, HC | 1 |
| Bogaard, JM | 1 |
| Paredi, P | 1 |
| Kharitonov, SA | 2 |
| Leak, D | 1 |
| Ward, S | 1 |
| Cramer, D | 1 |
| Barnes, PJ | 2 |
| Knower, MT | 1 |
| Dunagan, DP | 1 |
| Adair, NE | 1 |
| Chin, R | 1 |
| Herholz, C | 1 |
| Straub, R | 1 |
| Busato, A | 1 |
| Hadeli, KO | 1 |
| Siegel, EM | 1 |
| Sherrill, DL | 1 |
| Beck, KC | 1 |
| Enright, PL | 1 |
| Montuschi, P | 1 |
| Mayer, M | 1 |
| Dúbrava, I | 1 |
| Petrík, V | 1 |
| Mayerová, S | 1 |
| Fairshter, RD | 1 |
| Wilson, AF | 1 |
| Brandt, HJ | 1 |
| Hussels, M | 1 |
| Kimura, K | 1 |
| Rikitake, T | 1 |
| Matsumoto, T | 1 |
| Tateno, Y | 1 |
| Hasegawa, S | 1 |
| Aronow, WS | 1 |
| Ferlinz, J | 1 |
| Glauser, F | 1 |
| Hebbel, RP | 1 |
| Eaton, JW | 1 |
| Modler, S | 1 |
| Jacob, HS | 1 |
| Cordasco, EM | 1 |
| VanOrdstrand, HS | 1 |
| Newth, CJ | 1 |
| Nadel, JA | 1 |
| Vincent, J | 1 |
| Saltzman, HP | 1 |
| Ciulla, EM | 1 |
| Kuperman, AS | 1 |
| Zerbe, GO | 1 |
| Petty, TL | 2 |
| Sunyer, J | 1 |
| Antó, JM | 1 |
| Murillo, C | 1 |
| Saez, M | 1 |
| Dubois, P | 1 |
| Machiels, J | 1 |
| Smeets, F | 1 |
| Delwiche, JP | 1 |
| Lulling, J | 1 |
| Viegi, G | 2 |
| Paoletti, P | 1 |
| Prediletto, R | 1 |
| Di Pede, F | 1 |
| Carrozzi, L | 1 |
| Carmignani, G | 1 |
| Mammini, U | 1 |
| Lebowitz, MD | 1 |
| Giuntini, C | 1 |
| Moinard, J | 1 |
| Guenard, H | 1 |
| Zöllner, H | 1 |
| Wiersbitzky, S | 1 |
| Ballke, EH | 1 |
| Augst, D | 1 |
| Maass, B | 1 |
| Knudson, RJ | 1 |
| Kaltenborn, WT | 1 |
| Burrows, B | 2 |
| Andrews, AE | 1 |
| Cheney, J | 1 |
| Zerbe, G | 1 |
| Escarrabill, J | 1 |
| Marín, E | 1 |
| de la Riva, E | 1 |
| Giró, E | 1 |
| Estopà, R | 1 |
| Manresa, F | 1 |
| Snider, GL | 1 |
| Corriveau, ML | 1 |
| Rosen, BJ | 1 |
| Keller, CA | 1 |
| Chun, DS | 1 |
| Dolan, GF | 1 |
| Chinn, DJ | 1 |
| Askew, J | 1 |
| Rowley, L | 1 |
| Cotes, JE | 1 |
| Bennett, WD | 1 |
| Smaldone, GC | 1 |
| Lennon, PF | 1 |
| Schulman, LL | 1 |
| Enson, Y | 1 |
| Sue, DY | 1 |
| Oren, A | 1 |
| Hansen, JE | 1 |
| Wasserman, K | 1 |
| Fazzi, P | 1 |
| Giuliano, G | 1 |
| Begliomini, E | 1 |
| Fornai, E | 1 |
| Pistelli, G | 1 |
| Leikin, JB | 1 |
| Vogel, S | 1 |
| Bréant, J | 1 |
| Fleury, MF | 1 |
| van Lerberghe, A | 1 |
| Maurique, S | 1 |
| Frutiger, F | 1 |
| Blin, C | 1 |
| Boushy, SF | 1 |
| Osaki, Y | 1 |
| Makino, M | 1 |
| Lopez-Majano, V | 1 |
| Dutton, RE | 1 |
| Banner, AS | 1 |
| Vandenbergh, E | 1 |
| Clement, J | 1 |
| Van de Woestijne, KP | 1 |
| Emirgil, C | 1 |
| Sobol, BJ | 1 |
| Heymann, B | 1 |
| Shibutani, K | 1 |
| Mahlich, J | 1 |
| Keller, R | 1 |
| Herzog, H | 1 |
| Daly, WJ | 1 |
| Jain, BP | 1 |
| Pande, JN | 1 |
| Guleria, JS | 1 |
| Murphy, RL | 1 |
| Gaensler, EA | 1 |
| Redding, RA | 1 |
| Belleau, R | 1 |
| Keelan, PJ | 1 |
| Smith, AA | 1 |
| Goff, AM | 1 |
| Ferris, BG | 1 |
| Regan, GM | 1 |
| Tagg, B | 1 |
| Walford, J | 1 |
| Thomson, ML | 1 |
| Saidel, GM | 1 |
| Militano, TC | 1 |
| Chester, EH | 1 |
| Barach, AL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Upper and Lower Limb Maximal Exercise Capacities, Muscle Oxygenation and Energy Consumption During Tests in Patients With Interstitial Lung Disease[NCT06141603] | 30 participants (Anticipated) | Observational | 2023-11-25 | Recruiting | |||
| Reproducibility of 6 Minute Walk Tests for Oxygen Desaturation[NCT00740220] | 97 participants (Actual) | Observational | 2006-09-30 | Completed | |||
| Comparison of Different Functional Tests and Relation With Functional State and Quality of Life in Individuals With Chronic Obstructive Pulmonary Disease (COPD)[NCT00660738] | 11 participants (Actual) | Observational | 2007-01-31 | Completed | |||
| Evaluation of Reliability, Sensitivity and Validity of the Six Minute Step Test in Patients With Chronic Obstructive Pulmonary Disease and Its Relation With Predictors Markers of Risk of Death[NCT01298661] | 91 participants (Actual) | Interventional | 2011-02-28 | Completed | |||
| [NCT00005279] | 0 participants | Observational | 1971-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The kappa statistic is a measure of the quality of a test. It is a ratio. (NCT00740220)
Timeframe: All three 6MWTs should take place within 30 days
| Intervention | Ratio (Number) |
|---|---|
| Single Arm Prospective Observational Study | 0.62 |
"It was evaluated only in the COPD patients. BODE index is a prognostic index used in COPD patients, it is a 0-10 scale, where lower values means better prognostic. It is composed by other commonly used evaluations tools in COPD, Forced Expiratory Volume in the First second (from spirometry); classification in the scale ranging from 0-3, Body-mass index, classification in the scale ranging from 0-1; Six-minute walk test distance, classification in the scale ranging from 0-3 and referred dyspnea, classification in the scale ranging from 0-3.~It was only used the total score (0-10)" (NCT01298661)
Timeframe: Second day
| Intervention | units on a scale (Median) |
|---|---|
| COPD Patients | 3 |
"This test will be conducted by the Rater 1, the patient will step up and down one 20cm step during six minute. The Exertion Perception will be evaluated using BORG scale. This scale is a self-reported scale, which range from 0 to 10, where 0 means none exertion perception and 10 means very intense exertion perception (the highest the patient has ever felt). Lower values means that the patient feel less discomfort." (NCT01298661)
Timeframe: First day or second day of the protocol (random)
| Intervention | units on a scale (Median) |
|---|---|
| Healthy Young Subjects | 2 |
| Healthy Elderly Subjects | 2.5 |
| COPD Patients | 2 |
"This test will be conducted by the Rater 1, the patient will step up and down a 20cm step during six minute. It will be evaluated by a cardio monitor." (NCT01298661)
Timeframe: First day or second day of the protocol (random)
| Intervention | bpm (Mean) |
|---|---|
| Healthy Young Subjects | 154 |
| Healthy Elderly Subjects | 116 |
| COPD Patients | 117 |
"This test will be conducted by the Rater 1, the patient will step up and down a 20cm step during six minute. The performance will be evaluated by the number of the steps." (NCT01298661)
Timeframe: First day or second day of the protocol (random)
| Intervention | steps (Mean) |
|---|---|
| Healthy Young Subjects | 166.4 |
| Healthy Elderly Subjects | 114.0 |
| COPD Patients | 76.6 |
"This test will be conducted by the Rater 1, the patient will step up and down one 20cm step during six minute. It will be evaluated by a pulse oxymeter." (NCT01298661)
Timeframe: First day or second day of the protocol (random)
| Intervention | % of hemoglobin (Mean) |
|---|---|
| Healthy Young Subjects | 95.8 |
| Healthy Elderly Subjects | 95 |
| COPD Patients | 90.1 |
"This test will be conducted by the Rater 1, the subject will walk as far as it can in a 30m corridor during 6 minutes. The performance will be the distance (meters)that it walk." (NCT01298661)
Timeframe: First day or second day of the protocol (random)
| Intervention | meter (Mean) |
|---|---|
| Healthy Young Subjects | 643.5 |
| Healthy Elderly Subjects | 504.5 |
| COPD Patients | 380.4 |
"This test was conducted by the Rater 1, the subject walked as far as it could in a 30m corridor during 6 minutes. The Exertion Perception will be evaluated using BORG scale. This scale is a self-reported scale, which range from 0 to 10, where 0 means none exertion perception and 10 means very intense exertion perception (the highest the patient has ever felt). Lower values means that the patient feel less discomfort." (NCT01298661)
Timeframe: First day or second day of the protocol (random)
| Intervention | units on a scale (Median) |
|---|---|
| Healthy Young Subjects | 1 |
| Healthy Elderly Subjects | 0.5 |
| COPD Patients | 1 |
"This test will be conducted by the Rater 1, the subject will walk as far as it can in a 30m corridor during 6 minutes. It will be evaluated by a cardio monitor." (NCT01298661)
Timeframe: First day or second day of the protocol (random)
| Intervention | bpm (Mean) |
|---|---|
| Healthy Young Subjects | 143 |
| Healthy Elderly Subjects | 115 |
| COPD Patients | 113 |
"This test will be conducted by the Rater 1, the subject will walk as far as it can in a 30m corridor during 6 minutes. It will be evaluated by a pulse oxymeter." (NCT01298661)
Timeframe: First day or second day of the protocol (random)
| Intervention | % of hemoglobin (Mean) |
|---|---|
| Healthy Young Subjects | 96.7 |
| Healthy Elderly Subjects | 94.5 |
| COPD Patients | 90.4 |
"This test will be conducted by the Rater 1, the patient will step up and down one 20cm step during six minute.The Exertion Perception will be evaluated using BORG scale. This scale is a self-reported scale, which range from 0 to 10, where 0 means none exertion perception and 10 means very intense exertion perception (the highest the patient has ever felt). Lower values means that the patient feel less discomfort." (NCT01298661)
Timeframe: First day or second day of the protocol (random), 30 minutes after the first 6MST
| Intervention | units on a scale (Median) |
|---|---|
| Healthy Young Subjects | 2 |
| Healthy Elderly Subjects | 1.5 |
| COPD Patients | 2.5 |
"This test will be conducted by the Rater 1, the patient will step up and down a 20cm step during six minute. It will be evaluated by a cardio monitor." (NCT01298661)
Timeframe: First day or second day of the protocol (random), 30 minutes after the first 6MST
| Intervention | bpm (Mean) |
|---|---|
| Healthy Young Subjects | 159 |
| Healthy Elderly Subjects | 118 |
| COPD Patients | 117 |
"This test will be conducted by the Rater 1, the patient will step up and down a 20cm step during six minutes. The performance will be evaluated by the number of the climbs." (NCT01298661)
Timeframe: On the first or second day of evaluation (random), 30 minutes after the first 6MST.
| Intervention | steps (Mean) |
|---|---|
| Healthy Young Subjects | 170.7 |
| Healthy Elderly Subjects | 114.5 |
| COPD Patients | 82.4 |
"This test will be conducted by the Rater 1, the patient will step up and down one 20cm step during six minute. It will be evaluated by a pulse oxymeter ." (NCT01298661)
Timeframe: First day or second day of the protocol (random) ,30 minutes after the first 6MST
| Intervention | % of hemoglobin (Mean) |
|---|---|
| Healthy Young Subjects | 96 |
| Healthy Elderly Subjects | 94.9 |
| COPD Patients | 90.5 |
"This test will be conducted by the Rater 1, the subject will walk as far as it can in a 30m corridor during 6 minutes. The performance will be the distance (meters)that it walk." (NCT01298661)
Timeframe: On the first or second day of evaluation (random), 30 minutes after the first 6MWT.
| Intervention | meter (Mean) |
|---|---|
| Healthy Young Subjects | 648.2 |
| Healthy Elderly Subjects | 513.6 |
| COPD Patients | 391.0 |
"This test will be conducted by the Rater 1, the subject will walk as far as it can in a 30m corridor during 6 minutes. The Exertion Perception will be evaluated using BORG scale. This scale is a self-reported scale, which range from 0 to 10, where 0 means none exertion perception and 10 means very intense exertion perception (the highest the patient has ever felt). Lower values means that the patient feel less discomfort." (NCT01298661)
Timeframe: First day or second day of the protocol (random), 30 minutes after the first 6MWT
| Intervention | units on a scale (Median) |
|---|---|
| Healthy Young Subjects | 0.5 |
| Healthy Elderly Subjects | 0.5 |
| COPD Patients | 1 |
"This test will be conducted by the Rater 1, the subject will walk as far as it can in a 30m corridor during 6 minutes. It will be evaluated by a cardio monitor at rest and every two minutes of the test." (NCT01298661)
Timeframe: First day or second day of the protocol (random), 30 minutes after the first 6MWT
| Intervention | bpm (Mean) |
|---|---|
| Healthy Young Subjects | 144 |
| Healthy Elderly Subjects | 115 |
| COPD Patients | 112 |
"This test will be conducted by the Rater 1, the subject will walk as far as it can in a 30m corridor during 6 minutes. It will be evaluated by a pulse oxymeter." (NCT01298661)
Timeframe: ,First day or second day of the protocol (random) 30 minutes after the first 6MWT
| Intervention | % of hemoglobin (Mean) |
|---|---|
| Healthy Young Subjects | 96.4 |
| Healthy Elderly Subjects | 95.1 |
| COPD Patients | 90.3 |
"This test will be conducted by the Rater 2, the patient will step up down one 20cm step during six minute. The Exertion Perception will be evaluated using BORG scale. This scale is a self-reported scale, which range from 0 to 10, where 0 means none exertion perception and 10 means very intense exertion perception (the highest the patient has ever felt). Lower values means that the patient feel less discomfort." (NCT01298661)
Timeframe: On the third day of evaluation, seven days after the first day of evaluation. Since it was performed in the same day of the third 6MWT, the choice of the first test was random, and there was a 30 minute interval between them.
| Intervention | units on a scale (Median) |
|---|---|
| Healthy Young Subjects | 1 |
| Healthy Elderly Subjects | 2 |
| COPD Patients | 2.5 |
"This test will be conducted by the Rater 2, the patient will step up and down a 20cm step during six minute. It will be evaluated by a cardio monitor." (NCT01298661)
Timeframe: On the third day of evaluation, seven days after the first day of evaluation. Since it was performed in the same day of the third 6MWT, the choice of the first test was random, and there was a 30 minute interval between them.
| Intervention | bpm (Mean) |
|---|---|
| Healthy Young Subjects | 156 |
| Healthy Elderly Subjects | 117 |
| COPD Patients | 116 |
"This test will be conducted by the Rater 2, the patient will step up and down a 20cm step during six minutes. The performance will be evaluated by the number of the climbs." (NCT01298661)
Timeframe: On the third day of evaluation, seven days after the first day of evaluation. Since it was performed in the same day of the third 6MWT, the choice of the first test was random, and there was a 30 minute interval between them.
| Intervention | steps (Mean) |
|---|---|
| Healthy Young Subjects | 172.3 |
| Healthy Elderly Subjects | 111.3 |
| COPD Patients | 86.4 |
"This test will be conducted by the Rater 2, the patient will step up and down one 20cm step during six minute. It will be evaluated by a pulse oxymeter." (NCT01298661)
Timeframe: On the third day of evaluation, seven days after the first day of evaluation. Since it was performed in the same day of the third 6MWT, the choice of the first test was random, and there was a 30 minute interval between them.
| Intervention | % of hemoglobin (Mean) |
|---|---|
| Healthy Young Subjects | 95.8 |
| Healthy Elderly Subjects | 94.9 |
| COPD Patients | 90.3 |
"This test will be conducted by the Rater 2, the subject will walk as far as it can in a 30m corridor during 6 minutes. The performance will be the distance (meters)that it walk." (NCT01298661)
Timeframe: On the third day of evaluation, seven days after the first day of evaluation. Since it was performed in the same day of the third 6MST, the choice of the first test was random, and there was a 30 minute interval between them.
| Intervention | meter (Mean) |
|---|---|
| Healthy Young Subjects | 648.3 |
| Healthy Elderly Subjects | 502 |
| COPD Patients | 392.4 |
"This test will be conducted by the Rater 2, the subject will walk as far as it can in a 30m corridor during 6 minutes. The Exertion Perception will be evaluated using BORG scale. This scale is a self-reported scale, which range from 0 to 10, where 0 means none exertion perception and 10 means very intense exertion perception (the highest the patient has ever felt). Lower values means that the patient feel less discomfort." (NCT01298661)
Timeframe: On the third day of evaluation, seven days after the first day of evaluation. Since it was performed in the same day of the third 6MST, the choice of the first test was random, and there was a 30 minute interval between them.
| Intervention | units on a scale (Median) |
|---|---|
| Healthy Young Subjects | 1 |
| Healthy Elderly Subjects | 1 |
| COPD Patients | 2 |
"This test will be conducted by the Rater 2, the subject will walk as far as it can in a 30m corridor during 6 minutes. It will be evaluated by a cardio monitor." (NCT01298661)
Timeframe: On the third day of evaluation, seven days after the first day of evaluation. Since it was performed in the same day of the third 6MST, the choice of the first test was random, and there was a 30 minute interval between them.
| Intervention | bpm (Mean) |
|---|---|
| Healthy Young Subjects | 145 |
| Healthy Elderly Subjects | 112 |
| COPD Patients | 114 |
"This test will be conducted by the Rater 2, the subject will walk as far as it can in a 30m corridor during 6 minutes. It will be evaluated by a pulse oxymeter." (NCT01298661)
Timeframe: On the third day of evaluation, seven days after the first day of evaluation. Since it was performed in the same day of the third 6MST, the choice of the first test was random, and there was a 30 minute interval between them.
| Intervention | % of hemoglobin (Mean) |
|---|---|
| Healthy Young Subjects | 96.1 |
| Healthy Elderly Subjects | 94.7 |
| COPD Patients | 89.7 |
5 reviews available for carbon monoxide and Lung Diseases, Obstructive
| Article | Year |
|---|---|
Effect of carbon monoxide on the cardiorespiratory system. Carbon monoxide toxicity: physiology and biochemistry.
Topics: Adolescent; Adult; Angina Pectoris; Animals; Brain; Capillary Permeability; Carbon Monoxide; Carboxy | 1981 |
Health effects of outdoor air pollution. Committee of the Environmental and Occupational Health Assembly of the American Thoracic Society.
Topics: Adult; Aerosols; Air Pollutants; Air Pollution; Animals; Asthma; Biomarkers; Bronchial Hyperreactivi | 1996 |
Pulmonary physiology in interstitial lung disease: recent developments in diagnostic and prognostic implications.
Topics: Airway Resistance; Biopsy; Bronchoalveolar Lavage Fluid; Carbon Monoxide; Female; Forced Expiratory | 1996 |
Chronic obstructive pulmonary disease: a definition and implications of structural determinants of airflow obstruction for epidemiology.
Topics: Bronchi; Carbon Monoxide; Emphysema; Humans; Lung Compliance; Lung Diseases, Obstructive; Models, Bi | 1989 |
Arterial oxygenation and pulmonary hemodynamics in patients with chronic airways obstruction.
Topics: Blood Pressure; Carbon Monoxide; Cardiac Output; Chronic Disease; Hemodynamics; Humans; Hypertension | 1974 |
7 trials available for carbon monoxide and Lung Diseases, Obstructive
| Article | Year |
|---|---|
The effects of pentoxifylline on oxygenation, diffusion of carbon monoxide, and exercise tolerance in patients with COPD.
Topics: Carbon Monoxide; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Forced Expiratory Volu | 1995 |
Behavioral anti-smoking trial in chronic obstructive pulmonary disease patients.
Topics: Behavior Therapy; Breath Tests; Carbon Monoxide; Chewing Gum; Follow-Up Studies; Humans; Lung Diseas | 1995 |
Pulmonary effect of amiodarone in patients with heart failure. The Congestive Heart Failure-Survival Trial of Antiarrhythmic Therapy (CHF-STAT) Investigators (Veterans Affairs Cooperative Study No. 320).
Topics: Aged; Amiodarone; Carbon Monoxide; Heart Failure; Humans; Lung; Lung Diseases, Obstructive; Prospect | 1997 |
Re-breathing vs single-breath TLCO in patients with unequal ventilation and diffusion.
Topics: Adult; Aged; Carbon Monoxide; Female; Humans; Lung Diseases, Obstructive; Male; Middle Aged; Pulmona | 1998 |
Changes in transfer factor of the lung in response to bronchodilatation.
Topics: Adult; Asthma; Bronchial Provocation Tests; Bronchodilator Agents; Carbon Monoxide; Female; Humans; | 2000 |
Effect of carbon monoxide on exercise performance in chronic obstructive pulmonary disease.
Topics: Aged; Air Pollution; Blood Gas Analysis; Carbon Monoxide; Carboxyhemoglobin; Double-Blind Method; Hu | 1977 |
Reinforcing breath carbon monoxide reductions in chronic obstructive pulmonary disease.
Topics: Breath Tests; Carbon Monoxide; Chewing Gum; Follow-Up Studies; Forced Expiratory Volume; Humans; Lun | 1991 |
73 other studies available for carbon monoxide and Lung Diseases, Obstructive
| Article | Year |
|---|---|
The evolution of pulmonary function in childhood onset Mucopolysaccharidosis type I.
Topics: Adolescent; Adult; Age of Onset; Aged; Aged, 80 and over; Airway Obstruction; Carbon Monoxide; Child | 2021 |
Impact of air pollution on pulmonary function and respiratory symptoms in children. Longitudinal repeated-measures study.
Topics: Adolescent; Air Pollution; Carbon Monoxide; Child; Cohort Studies; Female; Forced Expiratory Volume; | 2010 |
Personal exposure monitoring of particulate matter, nitrogen dioxide, and carbon monoxide, including susceptible groups.
Topics: Adult; Aged; Air Pollutants; Air Pollution, Indoor; Carbon Monoxide; Child; Environmental Exposure; | 2002 |
[Measurement of diffusing capacity by the intrabreath method].
Topics: Aged; Breath Tests; Carbon Monoxide; Female; Humans; Lung Diseases, Obstructive; Male; Middle Aged; | 2005 |
[Quality control and other important issues in the measurement of pulmonary diffusing capacity by the one-breath method].
Topics: Carbon Monoxide; Functional Residual Capacity; Humans; Lung Diseases, Obstructive; Pulmonary Diffusi | 2007 |
Arterial oxygenation and pulmonary function with Saralasin in chronic lung disease.
Topics: Adult; Aged; Angiotensin II; Carbon Dioxide; Carbon Monoxide; Cardiac Output; Forced Expiratory Volu | 1983 |
Prediction of pulmonary hypertension from postural changes of pulmonary transfer factor.
Topics: Blood Pressure; Carbon Monoxide; Gravitation; Humans; Hypertension, Pulmonary; Lung Diseases, Obstru | 1984 |
Carbon monoxide diffusing capacity as predictor of outcome in systemic sclerosis.
Topics: Actuarial Analysis; Adult; Aged; Carbon Monoxide; Female; Follow-Up Studies; Forced Expiratory Volum | 1984 |
Relation of pulmonary vessel size to transfer factor in subjects with airflow obstruction.
Topics: Carbon Monoxide; Diffusion; Female; Humans; Lung Diseases, Obstructive; Male; Pulmonary Artery; Pulm | 1983 |
Amount of nicotine and carbon monoxide inhaled by smokers of low-tar, low-nicotine cigarettes.
Topics: Carbon Monoxide; Chromatography, Gas; Coronary Disease; Humans; Lung Diseases, Obstructive; Lung Neo | 1983 |
Overestimation of the single-breath carbon monoxide diffusing capacity in patients with air-flow obstruction.
Topics: Adolescent; Adult; Asthma; Carbon Monoxide; Cystic Fibrosis; Emphysema; Female; Humans; Lung Disease | 1984 |
Factors affecting expired waveform for carbon monoxide.
Topics: Adult; Analysis of Variance; Asthma; Carbon Monoxide; Female; Functional Residual Capacity; Humans; | 1984 |
Hypercapnic ventilatory control in patients with chronic airflow obstruction: a follow-up study.
Topics: Adult; Aged; Carbon Dioxide; Carbon Monoxide; Chemoreceptor Cells; Female; Follow-Up Studies; Forced | 1982 |
[Chronic non-specific disease of the respiratory system and measurable alterations in workers in the chromium-plating industry (author's transl)].
Topics: Adult; Carbon Monoxide; Chromium; Humans; Longitudinal Studies; Lung Diseases, Obstructive; Middle A | 1980 |
Distribution of ventilation and diffusing capacity in the normal and diseased lung.
Topics: Adolescent; Adult; Aged; Air Pressure; Argon; Carbon Monoxide; Female; Helium; Humans; Lung; Lung Di | 1981 |
Comparison of the single breath with the intrabreath method for the measurement of the carbon monoxide transfer factor in subjects with and without airways obstruction.
Topics: Adult; Aged; Breath Tests; Carbon Monoxide; Female; Humans; Lung Diseases; Lung Diseases, Obstructiv | 1995 |
Mortality and cancer morbidity in workers from an aluminium smelter with prebaked carbon anodes--Part III: Mortality from circulatory and respiratory diseases.
Topics: Adult; Aluminum; Arteriosclerosis; Carbon Monoxide; Cerebrovascular Disorders; Coal Tar; Cohort Stud | 1995 |
[Smoking in the workplace].
Topics: Carbon Monoxide; Cardiovascular Diseases; Humans; Lung Diseases, Obstructive; Lung Neoplasms; Nitro | 1994 |
Reduction of lung diffusion for carbon monoxide in patients with lung carcinoma.
Topics: Aged; Carbon Monoxide; Female; Hemoglobins; Humans; Lung Diseases, Obstructive; Lung Neoplasms; Male | 1993 |
Utility of complete dead space washout by real-time gas analysis in the measurement of transfer factor in patients with chronic airflow limitation.
Topics: Adult; Aged; Carbon Monoxide; Computer Systems; Female; Humans; Lung Diseases, Obstructive; Male; Mi | 1996 |
Air pollution and hospital admissions for respiratory causes in Minneapolis-St. Paul and Birmingham.
Topics: Aged; Air Pollution; Alabama; Carbon Monoxide; Confidence Intervals; Humans; Lung Diseases, Obstruct | 1997 |
[Diagnostic value of exercise diffusion capacity test on diffuse pulmonary fibrosis].
Topics: Adult; Carbon Monoxide; Exercise Test; Female; Humans; Lung; Lung Diseases, Interstitial; Lung Disea | 1996 |
Diffusing capacity of the lung for carbon monoxide.
Topics: Capillary Permeability; Carbon Monoxide; Exercise Test; Humans; Lung Diseases, Obstructive; Pulmonar | 1997 |
Respiratory effects of air pollution in chronic obstructive pulmonary disease: a three month prospective study.
Topics: Aged; Aged, 80 and over; Air Pollutants; Bronchodilator Agents; Carbon Monoxide; Cohort Studies; Fem | 1997 |
Pulmonary dysfunction in silica-exposed workers: a relationship to radiographic signs of silicosis and emphysema.
Topics: Adult; Age Factors; Aged; Carbon Monoxide; China; Forced Expiratory Volume; Humans; Lung; Lung Disea | 1999 |
The measurement of exhaled carbon monoxide is influenced by airflow obstruction.
Topics: Adult; Aged; Carbon Monoxide; Carboxyhemoglobin; Female; Humans; Lung Diseases, Obstructive; Lung Vo | 2000 |
Evaluation of diffusing capacity in patients with a restrictive lung disease.
Topics: Adult; Antimetabolites, Antineoplastic; Bleomycin; Carbon Monoxide; Humans; Lung Diseases, Obstructi | 2000 |
Influence of lung parenchymal destruction on the different indexes of the methacholine dose-response curve in COPD patients.
Topics: Administration, Inhalation; Adult; Aged; Breath Tests; Bronchial Hyperreactivity; Bronchial Provocat | 2000 |
Exhaled ethane, a marker of lipid peroxidation, is elevated in chronic obstructive pulmonary disease.
Topics: Biomarkers; Breath Tests; Carbon Monoxide; Ethane; Female; Forced Expiratory Volume; Humans; Lipid P | 2000 |
Baseline oxygen saturation predicts exercise desaturation below prescription threshold in patients with chronic obstructive pulmonary disease.
Topics: Aged; Carbon Monoxide; Exercise; Exercise Tolerance; Female; Forced Expiratory Volume; Humans; Hypox | 2001 |
Ultrasound-spirometry and capnography in horses: analysis of measurement reliability.
Topics: Animals; Capnography; Carbon Monoxide; Female; Horse Diseases; Horses; Lung Diseases, Obstructive; M | 2001 |
Predictors of oxygen desaturation during submaximal exercise in 8,000 patients.
Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Exercise Test; Female; Humans; Logistic Models; Lun | 2001 |
Predictors of oxygen desaturation during submaximal exercise in 8,000 patients.
Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Exercise Test; Female; Humans; Logistic Models; Lun | 2001 |
Predictors of oxygen desaturation during submaximal exercise in 8,000 patients.
Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Exercise Test; Female; Humans; Logistic Models; Lun | 2001 |
Predictors of oxygen desaturation during submaximal exercise in 8,000 patients.
Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Exercise Test; Female; Humans; Logistic Models; Lun | 2001 |
Predictors of oxygen desaturation during submaximal exercise in 8,000 patients.
Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Exercise Test; Female; Humans; Logistic Models; Lun | 2001 |
Predictors of oxygen desaturation during submaximal exercise in 8,000 patients.
Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Exercise Test; Female; Humans; Logistic Models; Lun | 2001 |
Predictors of oxygen desaturation during submaximal exercise in 8,000 patients.
Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Exercise Test; Female; Humans; Logistic Models; Lun | 2001 |
Predictors of oxygen desaturation during submaximal exercise in 8,000 patients.
Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Exercise Test; Female; Humans; Logistic Models; Lun | 2001 |
Predictors of oxygen desaturation during submaximal exercise in 8,000 patients.
Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Exercise Test; Female; Humans; Logistic Models; Lun | 2001 |
Exhaled carbon monoxide and nitric oxide in COPD.
Topics: Biomarkers; Breath Tests; Carbon Monoxide; Female; Humans; Lung Diseases, Obstructive; Male; Middle | 2001 |
[Value of investigating the diffusing capacity of the lung for CO in chronic obstructive disease (author's transl)].
Topics: Carbon Monoxide; Humans; Lung Diseases, Obstructive; Male; Pulmonary Diffusing Capacity | 1979 |
Relative sensitivities and specificities of tests for small airways obstruction.
Topics: Adult; Airway Obstruction; Carbon Monoxide; Female; Humans; Lung Diseases, Obstructive; Lung Volume | 1979 |
[Propagation of error, sensitivity and specificity of the CO gas transfer in various breath holding and steady state methods (author's transl)].
Topics: Asthma; Carbon Monoxide; Humans; Lung Diseases, Obstructive; Pulmonary Diffusing Capacity | 1979 |
[Clinical application of dynamic lung imaging by the single breath measurement with carbon-11-labeled CO2, CO and nitrogen-13-labeled N2 (author's transl)].
Topics: Adult; Carbon Dioxide; Carbon Monoxide; Carbon Radioisotopes; Female; Humans; Lung; Lung Diseases, O | 1979 |
Extreme but asymptomatic carboxyhemoglobinemia and chronic lung disease.
Topics: Aged; Carbon Monoxide; Carboxyhemoglobin; Chronic Disease; Hemoglobins; Humans; Hypoxia; Lung Diseas | 1978 |
Air pollution and COPD.
Topics: Air Pollutants; Cadmium; Carbon Monoxide; Chlorine; Chronic Disease; Humans; Lung; Lung Diseases, Ob | 1977 |
Pulmonary diffusing capacity measured at multiple intervals during a single exhalation in man.
Topics: Adult; Asthma; Blood Volume; Carbon Monoxide; Chronic Disease; Humans; Lung Diseases, Obstructive; M | 1977 |
[Determinations of the carbon monoxide diffusion at the early stages of chronic obstructive lung disease].
Topics: Capillaries; Carbon Monoxide; Humans; Lung Diseases, Obstructive; Membranes; Pulmonary Alveoli; Pulm | 1975 |
The spirographic "kink". A sign of emphysema.
Topics: Asthma; Carbon Monoxide; Emphysema; False Positive Reactions; Female; Forced Expiratory Flow Rates; | 1976 |
Effects of urban air pollution on emergency room admissions for chronic obstructive pulmonary disease.
Topics: Air Pollutants; Carbon Monoxide; Causality; Emergency Service, Hospital; Environmental Health; Human | 1991 |
Diffusion confusion.
Topics: Carbon Monoxide; Diffusion; Humans; Lung Diseases, Obstructive; Oxygen; Pulmonary Alveoli | 1990 |
CO transfer capacity as a determining factor of survival for severe hypoxaemic COPD patients under long-term oxygen therapy.
Topics: Aged; Carbon Monoxide; Female; Forced Expiratory Volume; Humans; Hypoxia; Lung Diseases, Obstructive | 1990 |
Carbon monoxide diffusing capacity, other indices of lung function, and respiratory symptoms in a general population sample.
Topics: Adolescent; Adult; Age Factors; Carbon Monoxide; Child; Female; Humans; Incidence; Italy; Longitudin | 1990 |
Determination of lung capillary blood volume and membrane diffusing capacity in patients with COLD using the NO-CO method.
Topics: Adult; Aged; Blood Volume Determination; Capillary Permeability; Carbon Monoxide; Chronic Disease; F | 1990 |
[Laboratory diagnostic monitoring of blood gas parameters in children during bronchologic studies].
Topics: Acid-Base Equilibrium; Acidosis, Respiratory; Anesthesia, General; Anesthesia, Inhalation; Asthma; B | 1990 |
Single breath carbon monoxide transfer factor in different forms of chronic airflow obstruction in a general population sample.
Topics: Adult; Aged; Asthma; Carbon Monoxide; Epidemiologic Methods; Female; Humans; Lung; Lung Diseases, Ob | 1990 |
Carbon monoxide assessment of smoking in chronic obstructive pulmonary disease.
Topics: Air Pollution; Breath Tests; Carbon Monoxide; Female; Follow-Up Studies; Forced Expiratory Volume; H | 1989 |
[The tobacco habit in patients using home oxygen therapy].
Topics: Aged; Carbon Monoxide; Humans; Hypoxia; Lung Diseases, Obstructive; Middle Aged; Oxygen Inhalation T | 1989 |
Effect of posture, hydralazine, and nifedipine on hemodynamics, ventilation, and gas exchange in patients with chronic obstructive pulmonary disease.
Topics: Carbon Dioxide; Carbon Monoxide; Hemodynamics; Humans; Hydralazine; Hypertension, Pulmonary; Lung Di | 1988 |
Measurement technique influences the response of transfer factor (TICO) to salbutamol in patients with airflow limitation.
Topics: Adult; Aged; Albuterol; Breath Tests; Carbon Monoxide; Female; Humans; Lung Diseases, Obstructive; M | 1988 |
Use of aerosols to estimate mean air-space size in chronic obstructive pulmonary disease.
Topics: Aerosols; Carbon Monoxide; Humans; Lung; Lung Diseases, Obstructive; Lung Volume Measurements; Refer | 1988 |
Effect of chronic airways obstruction on measurement of the single-breath carbon-monoxide-diffusing capacity.
Topics: Aged; Carbon Monoxide; Female; Humans; Lung Diseases, Obstructive; Male; Middle Aged; Pulmonary Diff | 1987 |
Diffusing capacity for carbon monoxide as a predictor of gas exchange during exercise.
Topics: Asbestosis; Carbon Monoxide; Humans; Lung Diseases; Lung Diseases, Obstructive; Male; Middle Aged; P | 1987 |
[Respiratory function in chemical workers].
Topics: Carbon Monoxide; Chemical Industry; Forced Expiratory Flow Rates; Forced Expiratory Volume; Humans; | 1985 |
Carbon monoxide levels in cardiac patients in an urban emergency department.
Topics: Asthma; Carbon Monoxide; Carboxyhemoglobin; Coronary Disease; Heart Diseases; Heart Failure; Hemoglo | 1986 |
[Steady-state carbon monoxide transfer during progressive muscular exercise in patients. Relation to PaO2. Value of specific VCO].
Topics: Aging; Carbon Monoxide; Humans; Hypoxia; Lung Diseases; Lung Diseases, Obstructive; Male; Middle Age | 1985 |
[Scandinavian seminar: environmental pollution and heart and lung diseases].
Topics: Adult; Air Pollutants; Air Pollution; Asbestos; Asthma; Bronchitis; Carbon Monoxide; Child; Environm | 1974 |
The use of expiratory forced flows for determining response to bronchodilator therapy.
Topics: Airway Resistance; Bronchodilator Agents; Carbon Monoxide; Chronic Disease; Humans; Isoproterenol; L | 1972 |
[Limitation of clinical examinations. V. Pulmonary diffusing capacity].
Topics: Capillaries; Carbon Monoxide; Hemoglobins; Humans; Lung Diseases, Obstructive; Methods; Pulmonary Al | 1972 |
Regulation of respiration during oxygen breathing in chronic obstructive lung disease.
Topics: Acidosis; Airway Resistance; Arteries; Bicarbonates; Carbon Dioxide; Carbon Monoxide; Chronic Diseas | 1973 |
Pulmonary function in chronic alcoholism.
Topics: Adult; Alcoholism; Carbon Monoxide; Chronic Disease; Female; Humans; Lung Compliance; Lung Diseases, | 1973 |
Course and prognosis of patients with advanced chronic obstructive pulmonary disease. Evaluation by means of functional indices.
Topics: Adult; Aged; Blood Gas Analysis; Bronchitis; Carbon Dioxide; Carbon Monoxide; Electrocardiography; E | 1973 |
Pulmonary function in alcoholics.
Topics: Adult; Alcoholism; Bronchitis; Carbon Monoxide; Disease Susceptibility; Dyspnea; Ethanol; Female; Hu | 1974 |
["Steady-state" diffusing capacity of Filley in relation to the time of carbon monoxide breathing (author's transl)].
Topics: Adult; Aged; Blood Gas Analysis; Carbon Monoxide; Carboxyhemoglobin; Humans; Lung Diseases; Lung Dis | 1974 |
Single-breath gas distribution in chronic obstructive lung disease. Isoproterenol effect on neon dilution volume and diffusing capacity.
Topics: Adult; Airway Resistance; Asthma; Bronchitis; Carbon Monoxide; Diffusion; Female; Humans; Indicator | 1971 |
Membrane diffusing capacity and pulmonary capillary blood volume in chronic obstructive lung disease.
Topics: Blood Volume; Bronchitis; Capillaries; Carbon Monoxide; Chronic Disease; Female; Hemoglobins; Humans | 1972 |
Low exposure to asbestos. Gas exchange in ship pipe coverers and controls.
Topics: Airway Resistance; Asbestosis; Carbon Dioxide; Carbon Monoxide; Environmental Exposure; Follow-Up St | 1972 |
The relative importance of clinical, radiological and pulmonary function variables in evaluating asbestosis and chronic obstructive airway disease in asbestos workers.
Topics: Adult; Asbestosis; Carbon Monoxide; Chronic Disease; Cough; Diagnosis, Differential; Humans; Lung Di | 1971 |
Pulmonary gas transport characterization by a dynamic model.
Topics: Adult; Aged; Carbon Monoxide; Chronic Disease; Humans; Lung Diseases, Obstructive; Middle Aged; Mode | 1971 |
The ambient air, the good of it and the bad of it: the development of therapeutic gases and air pollution.
Topics: Air Pollution; Carbon Monoxide; Gases; Helium; Humans; Hyperbaric Oxygenation; Lung Diseases, Obstru | 1971 |